Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

131.25 +4.16 (+3.27%)
Streaming Delayed Price Updated: 3:57 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Avoid
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 We Avoid
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Economy Government Stocks
News headline image
1 High-Flying Stock with Solid Fundamentals and 2 We Avoid
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
Repligen Corp (NASDAQ:RGEN) Stock Falls Despite Q4 Earnings Beat as 2026 Guidance Disappoints ↗
Via Chartmill
Topics Earnings
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
News headline image
2 Growth Stocks Set to Flourishand 1 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Brown Capital Dumps 190,000 AppFolio Shares Worth $45.1 Million ↗
Via The Motley Fool
News headline image
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy
News headline image
3 Healthcare Stocks We’re Skeptical Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
Repligen trades at $124.97 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 6.6... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 
Via StockStory
Topics Economy Stocks
News headline image
Repligen (RGEN) Q4 2025 Earnings Call Transcript ↗
Repligen (RGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The... 
Via StockStory
News headline image
Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 of Wall Street’s Favorite Stocks Worth Investigating and 1 We Avoid
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
3 Volatile Stocks Walking a Fine Line
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
News headline image
2 Cash-Producing Stocks to Target This Week and 1 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
3 Reasons to Sell RGEN and 1 Stock to Buy Instead
Repligen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.3%. The stock now trades at $163.29, marking a 36.5% gain. This was partly due to its solid... 
Via StockStory
Topics Stocks
News headline image
3 High-Flying Stocks That Fall Short
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
News headline image
Why Repligen (RGEN) Shares Are Sliding Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.9% in the afternoon session after the company presented at the JPMorgan Healthcare Conference and shared its sales... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Challenges
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
1 Volatile Stock to Target This Week and 2 We Turn Down
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
News headline image
Why Repligen (RGEN) Stock Is Trading Up Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 5.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate... 
Via StockStory
Topics Artificial Intelligence Economy Stocks
News headline image
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Cash-Producing Stocks We Approach with Caution
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers. 
Via StockStory
News headline image
5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call
Repligen’s third quarter saw revenue and non-GAAP profit exceed Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s strong top-line performance to... 
Via StockStory
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.